Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

[1]  Jennifer G. Robinson,et al.  Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[2]  S. Daniels,et al.  Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[3]  Matthew K. Ito,et al.  Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[4]  Jennifer G. Robinson,et al.  Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[5]  D. Rader,et al.  Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. , 2011, Journal of clinical lipidology.

[6]  E. Bruckert,et al.  Lowering LDL-cholesterol through diet: potential role in the statin era , 2011, Current opinion in lipidology.

[7]  G. Moneta.  Does Carotid Intima-Media Thickness Regression Predict Reduction of Cardiovascular Events? A Meta-Analysis of 41 Randomized Trials , 2011 .

[8]  Megan E. Piper,et al.  Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. , 2011, American heart journal.

[9]  C. Rochitte,et al.  Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. , 2010, Atherosclerosis.

[10]  P. Galan,et al.  Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial , 2010, BMJ : British Medical Journal.

[11]  G. Steinbeck,et al.  OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction , 2010, Circulation.

[12]  J. Geleijnse,et al.  n-3 fatty acids and cardiovascular events after myocardial infarction. , 2010, The New England journal of medicine.

[13]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[14]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[15]  J. Kastelein,et al.  Long-term LDL-c lowering in heterozygous familial hypercholesterolemia normalizes carotid intima-media thickness. , 2010, Atherosclerosis.

[16]  Lawrence Joseph,et al.  The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. , 2010, Journal of the American College of Cardiology.

[17]  G. Vilahur,et al.  Nutraceuticals and atherosclerosis: human trials. , 2010, Cardiovascular therapeutics.

[18]  S. Yokoyama,et al.  Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. , 2010, Journal of atherosclerosis and thrombosis.

[19]  G. Watts,et al.  A new model of care for familial hypercholesterolaemia from Western Australia: closing a major gap in preventive cardiology. , 2010, Heart, lung & circulation.

[20]  P. R. Kamstrup.  Lipoprotein(a) and ischemic heart disease--a causal association? A review. , 2010, Atherosclerosis.

[21]  I. Holme,et al.  Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. , 2010, The American journal of cardiology.

[22]  Pierre Amarenco,et al.  Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. , 2010, Atherosclerosis.

[23]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[24]  C. Perry.  Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia. , 2010, Paediatric drugs.

[25]  E. Sijbrands,et al.  The risk of tendon xanthomas in familial hypercholesterolaemia is influenced by variation in genes of the reverse cholesterol transport pathway and the low-density lipoprotein oxidation pathway. , 2010, European heart journal.

[26]  J. Hsia,et al.  Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. , 2010, Journal of the American College of Cardiology.

[27]  J. Kastelein,et al.  Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. , 2010, Atherosclerosis.

[28]  Jennifer G. Robinson,et al.  Current and Emerging Therapies in Hypercholesterolemia: Focus on Colesevelam , 2010 .

[29]  E. Ros,et al.  Impact of low-density lipoprotein receptor mutational class on carotid atherosclerosis in patients with familial hypercholesterolemia. , 2010, Atherosclerosis.

[30]  A. Marais,et al.  Efficacy criteria and cholesterol targets for LDL apheresis. , 2010, Atherosclerosis.

[31]  Sharp Collaborative Group.  Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.

[32]  E. Sijbrands,et al.  Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis. , 2009, Atherosclerosis.

[33]  Robert Dufour,et al.  Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .

[34]  D. Lloyd‐Jones,et al.  Systematic Examination of the Updated Framingham Heart Study General Cardiovascular Risk Profile , 2009, Circulation.

[35]  T. Jacobson.  Myopathy with statin–fibrate combination therapy: clinical considerations , 2009, Nature Reviews Endocrinology.

[36]  O. Wagner,et al.  Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or =40 years of age). , 2009, European heart journal.

[37]  Jonathan C. Cohen,et al.  PCSK9: a convertase that coordinates LDL catabolism Published, JLR Papers in Press, November 19, 2008. , 2009, Journal of Lipid Research.

[38]  Gordon H Guyatt,et al.  Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis , 2009, BMJ : British Medical Journal.

[39]  Jennifer G. Robinson,et al.  Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. , 2009, Journal of the American College of Cardiology.

[40]  S. Humphries,et al.  Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia , 2008, Heart.

[41]  Jennifer G. Robinson.  Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin , 2008, Vascular health and risk management.

[42]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[43]  M. Clemente,et al.  Ezetimibe as Monotherapy in the Treatment of Hypercholesterolemia in Children and Adolescents , 2009, Journal of pediatric endocrinology & metabolism : JPEM.

[44]  S. Nissen.  Analyses of cancer data from three ezetimibe trials. , 2009, The New England journal of medicine.

[45]  J. Witteman,et al.  Efficacy of statins in familial hypercholesterolaemia: a long term cohort study , 2008, BMJ : British Medical Journal.

[46]  B. Kleinman,et al.  Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. , 2008, The American journal of cardiology.

[47]  P. Kwiterovich.  Recognition and management of dyslipidemia in children and adolescents. , 2008, The Journal of clinical endocrinology and metabolism.

[48]  J. Kastelein,et al.  Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. , 2008, Journal of the American College of Cardiology.

[49]  S. Humphries,et al.  Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study , 2008, European heart journal.

[50]  D. Panagiotakos,et al.  Long-term prognostic factors of young patients (≤ 35 years) having acute myocardial infarction: the detrimental role of continuation of smoking , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[51]  R. Alonso,et al.  Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. , 2008, Atherosclerosis.

[52]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[53]  S. Humphries,et al.  Familial hypercholesterolaemia: summary of NICE guidance , 2008, BMJ : British Medical Journal.

[54]  Jennifer G. Robinson,et al.  Is it over for ezetimibe? , 2008, Expert review of cardiovascular therapy.

[55]  S. Daniels,et al.  Lipid Screening and Cardiovascular Health in Childhood , 2008, Pediatrics.

[56]  Anders G. Olsson,et al.  Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment , 2008, Circulation.

[57]  G. Thompson.  Recommendations for the use of LDL apheresis. , 2008, Atherosclerosis.

[58]  C. Boileau,et al.  Genetic heterogeneity of autosomal dominant hypercholesterolemia , 2007, Clinical genetics.

[59]  T. Graham.  Statin Treatment in Children With Familial Hypercholesterolemia: The Younger, the Better , 2008 .

[60]  E. Sijbrands,et al.  Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance , 2008, European Journal of Human Genetics.

[61]  J. Viikari,et al.  Utility of Currently Recommended Pediatric Dyslipidemia Classifications in Predicting Dyslipidemia in Adulthood: Evidence From the Childhood Determinants of Adult Health (CDAH) Study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study , 2008, Circulation.

[62]  R. Huupponen,et al.  The Cardiovascular Risk in Young Finns Study , 2008 .

[63]  D. Wald,et al.  Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis , 2007, BMJ : British Medical Journal.

[64]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit , 2007, European heart journal.

[65]  E. Stein.  Statins and children: whom do we treat and when? , 2007, Circulation.

[66]  S. Ylä-Herttuala,et al.  Current status of cardiovascular gene therapy. , 2007, Molecular Therapy.

[67]  M. Freeman,et al.  Screening and Treatment for Lipid Disorders in Children and Adolescents: Systematic Evidence Review for the US Preventive Services Task Force , 2007, Pediatrics.

[68]  G. Watts,et al.  Familial hypercholesterolemia: a missed opportunity in preventive medicine , 2007, Nature Clinical Practice Cardiovascular Medicine.

[69]  Jennifer G. Robinson,et al.  Safety of aggressive lipid management. , 2007, Journal of the American College of Cardiology.

[70]  Marc S Jacobson,et al.  Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. , 2007, Circulation.

[71]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[72]  A. Soutar,et al.  Mechanisms of Disease: genetic causes of familial hypercholesterolemia , 2007, Nature Clinical Practice Cardiovascular Medicine.

[73]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[74]  J. Liao.  Safety and efficacy of statins in Asians. , 2007, The American journal of cardiology.

[75]  Jonathan C. Cohen,et al.  Molecular biology of PCSK9: its role in LDL metabolism. , 2007, Trends in biochemical sciences.

[76]  C. Keller.  Apheresis in Coronary Heart Disease With Elevated Lp (a): A Review of Lp (a) As a Risk Factor and Its Management , 2007, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[77]  S. Humphries,et al.  Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk , 2006, Journal of Medical Genetics.

[78]  Jennifer G. Robinson,et al.  Identifying patients for aggressive cholesterol lowering: the risk curve concept. , 2006, The American journal of cardiology.

[79]  J. Strong,et al.  Pathobiological Determinants of Atherosclerosis in Youth Risk Scores Are Associated With Early and Advanced Atherosclerosis , 2006, Pediatrics.

[80]  M. Castro Cabezas,et al.  Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. , 2006, Journal of the American Dietetic Association.

[81]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[82]  P. Moriarty.  LDL-apheresis therapy , 2006, Current treatment options in cardiovascular medicine.

[83]  S. Daniels,et al.  Sensitivity and Specificity of Pediatric Lipid Determinations for Adult Lipid Status: Findings From the Princeton Lipid Research Clinics Prevalence Program Follow-up Study , 2006, Pediatrics.

[84]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[85]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[86]  P. Thompson,et al.  An assessment of statin safety by muscle experts. , 2006, The American journal of cardiology.

[87]  N. Chalasani,et al.  An assessment of statin safety by hepatologists. , 2006, The American journal of cardiology.

[88]  J. Mckenney,et al.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. , 2006, The American journal of cardiology.

[89]  A. Ek,et al.  Disease Knowledge and Adherence to Treatment in Patients With Familial Hypercholesterolemia , 2006, The Journal of cardiovascular nursing.

[90]  A. Goldberg,et al.  Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. , 2006, The American journal of cardiology.

[91]  Jennifer G. Robinson,et al.  Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. , 2005, Journal of the American College of Cardiology.

[92]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[93]  I. Young,et al.  Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. , 2005, Atherosclerosis.

[94]  P. Hopkins,et al.  Efficacy and Safety of Lovastatin Therapy in Adolescent Girls With Heterozygous Familial Hypercholesterolemia , 2005, Pediatrics.

[95]  S. Humphries,et al.  Implementation of cascade testing for the detection of familial hypercholesterolaemia , 2005, Current opinion in lipidology.

[96]  Zahi A Fayad,et al.  Risk scores predict atherosclerotic lesions in young people. , 2005, Archives of internal medicine.

[97]  P. Sager,et al.  Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. , 2005, American heart journal.

[98]  M. Trip,et al.  Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. , 2005, The American journal of cardiology.

[99]  E. Sijbrands,et al.  The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients , 2004, Journal of internal medicine.

[100]  S. Humphries,et al.  Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia , 2004, Heart.

[101]  F. V. van Bockxmeer,et al.  Lipid disorders and mutations in the APOB gene. , 2004, Clinical chemistry.

[102]  Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled clinical trial☆ , 2004 .

[103]  Carolyn M Hutter,et al.  Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. , 2004, American journal of epidemiology.

[104]  S. Humphries,et al.  Familial hypercholesterolemia and coronary heart disease: a HuGE association review. , 2004, American journal of epidemiology.

[105]  S. Humphries,et al.  Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial , 2004, American journal of medical genetics. Part A.

[106]  F. Civeira,et al.  Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. , 2004, Atherosclerosis.

[107]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[108]  W. Voelker,et al.  The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia , 1994, The clinical investigator.

[109]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[110]  T. Laitinen,et al.  Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. , 2003, JAMA.

[111]  Wei Chen,et al.  Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. , 2003, JAMA.

[112]  I. Amano,et al.  Changes in Oxidative Stress and Microcirculation by Low‐density Lipoprotein Apheresis , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[113]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[114]  B. McCrindle,et al.  Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. , 2003, The Journal of pediatrics.

[115]  A. Schwarting,et al.  Differential Indication of Lipoprotein Apheresis During Pregnancy , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[116]  S. Humphries,et al.  A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. , 2003, Atherosclerosis.

[117]  J. Kastelein,et al.  Early statin therapy restores endothelial function in children with familial hypercholesterolemia. , 2002, Journal of the American College of Cardiology.

[118]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[119]  G. Bonsel,et al.  Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. , 2002, European heart journal.

[120]  Jonathan C. Cohen,et al.  ARH Is a Modular Adaptor Protein That Interacts with the LDL Receptor, Clathrin, and AP-2* , 2002, The Journal of Biological Chemistry.

[121]  M. Mercuri,et al.  Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Trial With Simvastatin , 2002, Circulation.

[122]  G. Hansson.  Vaccination against atherosclerosis: science or fiction? , 2002, Circulation.

[123]  F. Oort,et al.  Parental attitude towards genetic testing for familial hypercholesterolaemia in children , 2002, Journal of medical genetics.

[124]  S. Srinivasan,et al.  Distribution and correlates of non-high-density lipoprotein cholesterol in children: the Bogalusa Heart Study. , 2002, Pediatrics.

[125]  B. McCrindle,et al.  A Randomized Crossover Trial of Combination Pharmacologic Therapy in Children with Familial Hyperlipidemia , 2002, Pediatric Research.

[126]  D. Gaudet,et al.  Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia , 2002, Circulation.

[127]  P. J. Marang-van de Mheen,et al.  Getting insurance after genetic screening on familial hypercholesterolaemia; the need to educate both insurers and the public to increase adherence to national guidelines in the Netherlands , 2002, Journal of epidemiology and community health.

[128]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[129]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[130]  S. Grundy.  United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. , 2001, The American journal of cardiology.

[131]  J. Mckenney,et al.  Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia , 2001, Clinical cardiology.

[132]  Jonathan C. Cohen,et al.  Autosomal Recessive Hypercholesterolemia Caused by Mutations in a Putative LDL Receptor Adaptor Protein , 2001, Science.

[133]  C. White,et al.  Evaluation of the Antihyperlipidemic Properties of Dietary Supplements , 2001, Pharmacotherapy.

[134]  J. Borén,et al.  The Molecular Mechanism for the Genetic Disorder Familial Defective Apolipoprotein B100* , 2001, The Journal of Biological Chemistry.

[135]  F. Chaves,et al.  Importance of HDL cholesterol levels and the total/ HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. , 2001, European heart journal.

[136]  M. Trip,et al.  Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial , 2001, The Lancet.

[137]  D. Illingworth,et al.  Management of hypercholesterolemia. , 2001, The Medical clinics of North America.

[138]  D. Bhatnagar,et al.  Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia , 2000, BMJ : British Medical Journal.

[139]  N. Grishin,et al.  Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. , 2000, Science.

[140]  I. Rabbone,et al.  Clinical Expression of Familial Hypercholesterolemia in Clusters of Mutations of the LDL Receptor Gene That Cause a Receptor-Defective or Receptor-Negative Phenotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[141]  J. Strong,et al.  Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[142]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[143]  J. Davignon,et al.  Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations. , 2000, Atherosclerosis.

[144]  P. Hopkins,et al.  Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. , 1999, JAMA.

[145]  D. Capuzzi,et al.  Treatment of hyperlipidemia with combined niacin-statin regimens. , 1998, The American journal of cardiology.

[146]  A. Goldberg.  Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. , 1998, The American journal of cardiology.

[147]  H. Mabuchi,et al.  Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia , 1998 .

[148]  H. Mcgill,et al.  Determinants of atherosclerosis in the young , 1998 .

[149]  J. Cleeman,et al.  Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey. , 1998, Preventive medicine.

[150]  J. Després,et al.  Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians. , 1998, The American journal of cardiology.

[151]  R. Tracy,et al.  Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. , 1998, The New England journal of medicine.

[152]  A. Gotto,et al.  Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system , 1998 .

[153]  American Academy of Pediatrics. Committee on Nutrition. Cholesterol in childhood. , 1998, Pediatrics.

[154]  B. McCrindle,et al.  Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. , 1997, The Journal of pediatrics.

[155]  T. Imaizumi,et al.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. , 1997, Circulation.

[156]  E. Rimm,et al.  Failure of current guidelines for cholesterol screening in urban African-American adolescents. , 1996, Pediatrics.

[157]  S. Tonstad,et al.  Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. , 1996, The Journal of pediatrics.

[158]  S. Srinivasan,et al.  Usefulness of childhood low-density lipoprotein cholesterol level in predicting adult dyslipidemia and other cardiovascular risks. The Bogalusa Heart Study. , 1996, Archives of internal medicine.

[159]  S. Srinivasan,et al.  The relation of apolipoprotein E polymorphism to multiple cardiovascular risk in children: the Bogalusa Heart Study. , 1996, Atherosclerosis.

[160]  J. Reiber,et al.  LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. , 1996, Circulation.

[161]  J. T. Clarke,et al.  Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. , 1996, Pediatrics.

[162]  H. Büller,et al.  Short-Term Efficacy and Safety of Pravastatin in 72 Children with Familial Hypercholesterolemia , 1996, Pediatric Research.

[163]  J. Ferrières,et al.  Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. , 1995, Circulation.

[164]  G. Huster,et al.  Definition and application of the discretionary screening indicators according to the National Cholesterol Education Program for Children and Adolescents. , 1995, The Journal of pediatrics.

[165]  J. Viikari,et al.  Tracking and predictiveness of serum lipid and lipoprotein measurements in childhood: a 12-year follow-up. The Cardiovascular Risk in Young Finns study. , 1994, American journal of epidemiology.

[166]  T. Pearson,et al.  Challenges to implementing the current pediatric cholesterol screening guidelines into practice. , 1994, Pediatrics.

[167]  A. Soutar,et al.  Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia. , 1993, Atherosclerosis.

[168]  M. Leppert,et al.  Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. , 1993, The American journal of cardiology.

[169]  J. Newburger,et al.  Niacin treatment of hypercholesterolemia in children. , 1993, Pediatrics.

[170]  J. Huttunen,et al.  Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. , 1993, Annals of medicine.

[171]  K. Usadel,et al.  Familial defective apolipoprotein B-100: mild hypercholesterolaemia without atherosclerosis in a homozygous patient , 1992, The Lancet.

[172]  E. Muls,et al.  Simvastatin use in children , 1992, The Lancet.

[173]  Richard H. Myers,et al.  Familial Lipoprotein Disorders in Patients With Premature Coronary Artery Disease , 1992, Circulation.

[174]  Ncep Expert Panel on Blood Cholesterol Levels in Childr Adolescents.  National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. , 1992, Pediatrics.

[175]  H. Hobbs,et al.  Molecular genetics of the LDL receptor gene in familial hypercholesterolemia , 1992, Human mutation.

[176]  Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. , 1991, BMJ.

[177]  L. Kuller,et al.  Cholesterol screening in childhood: sixteen-year Beaver County Lipid Study experience. , 1991, The Journal of pediatrics.

[178]  V. Armstrong,et al.  The HELP‐LDL‐apheresis multicentre study, an angiographically assessed trial on the role of LDL‐apheresis in the secondary prevention of coronary heart disease , 1991, European journal of clinical investigation.

[179]  G. Koren,et al.  Assessing pain and analgesia with a lidocaine-prilocaine emulsion in infants and toddlers during venipuncture. , 1991, The Journal of pediatrics.

[180]  S. Srinivasan,et al.  Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study. , 1991, American journal of epidemiology.

[181]  M. Hayden,et al.  Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[182]  P. Allhoff,et al.  Bogalusa Heart Study , 2020, Encyclopedia of Behavioral Medicine.

[183]  J P Matts,et al.  Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) , 1990, The New England journal of medicine.

[184]  R. Krauss,et al.  Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. , 1990, Journal of lipid research.

[185]  S. Hunt,et al.  Population-based frequency of dyslipidemia syndromes in coronary-prone families in Utah. , 1990, Archives of internal medicine.

[186]  K. Christoffel,et al.  Family History Evaluation as a Predictive Screen for Childhood Hypercholesterolemia , 1989, Pediatrics.

[187]  J. Huttunen,et al.  Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. , 1988, JAMA.

[188]  D. Freedman,et al.  Cardiovascular risk factors from birth to 7 years of age: the Bogalusa Heart Study. Serum lipids and lipoproteins. , 1987, Pediatrics.

[189]  H. Hobbs,et al.  Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. , 1987, The New England journal of medicine.

[190]  R. Goldberg,et al.  Plasma Lipoprotein Distribution of Apolipoprotein E in Familial Hypercholesterolemia , 1987, Arteriosclerosis.

[191]  B. Horsthemke,et al.  Identification of deletions in the human low density lipoprotein receptor gene. , 1987, Journal of medical genetics.

[192]  Gerald S. Berenson,et al.  Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa heart study , 1986 .

[193]  L. Chambless,et al.  Patterns of dyslipoproteinemia in selected North American populations. The Lipid Research Clinics Program Prevalence Study. , 1986, Circulation.

[194]  J. Lloyd,et al.  Double blind trial of bezafibrate in familial hypercholesterolaemia. , 1985, Archives of disease in childhood.

[195]  Roger A. Renfrew,et al.  Lipid Research Clinics Program. , 1984, JAMA.

[196]  G. Heiss,et al.  Lipid and lipoprotein distributions in white children ages 6-19 yr. The Lipid Research Clinics Program Prevalence Study. , 1981, Journal of chronic diseases.

[197]  M. Brown,et al.  The LDL receptor locus and the genetics of familial hypercholesterolemia. , 1979, Annual review of genetics.

[198]  C. Caceres,et al.  Coronary drug project. , 1978, JAMA.

[199]  W. Martin,et al.  Colestipol hydrochloride in hypercholesterolemic patients--effect on serum cholesterol and mortality. , 1978, Journal of chronic diseases.

[200]  C. Mcgilchrist,et al.  Low fat, low cholesterol diet in secondary prevention of coronary heart disease. , 1978, Advances in experimental medicine and biology.

[201]  B. Friis‐Hansen,et al.  Neonatal diagnosis of familial type II hyperlipoproteinemia. , 1976, Pediatrics.

[202]  A. Khachadurian,et al.  Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. , 1973, Nutrition and metabolism.

[203]  Joseph L. Goldstein,et al.  Hyperlipidemia in Coronary Heart Disease , 1973 .

[204]  P. Allhoff,et al.  Controlled trial of soya-bean oil in myocardial infarction. , 1968, Lancet.

[205]  P. Leren.  The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. A controlled clinical trial. , 1966, Acta medica Scandinavica. Supplementum.

[206]  Charles R. Scriver,et al.  Committee on Nutrition , 1956, Pediatric Clinical Practice Guidelines & Policies.